Keros Therapeutics Announces Update to Participation at the Goldman Sachs 44th Annual Global Healthcare Conference
June 12 2023 - 8:00AM
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel treatments for patients suffering from
hematological, pulmonary and cardiovascular disorders with high
unmet medical need, today announced that it will not be
participating in the previously announced fireside chat
presentation during the Goldman Sachs 44th Annual Healthcare
Conference on Wednesday, June 14, 2023.
About Keros Therapeutics, Inc.Keros is a
clinical-stage biopharmaceutical company focused on the discovery,
development and commercialization of novel treatments for patients
suffering from hematological, pulmonary and cardiovascular
disorders with high unmet medical need. Keros is a leader in
understanding the role of the transforming growth factor-beta
family of proteins, which are master regulators of red blood cell
and platelet production as well as of the growth, repair and
maintenance of a number of tissues, including blood vessels and
heart tissue. Keros’ lead protein therapeutic product candidate,
KER-050, is being developed for the treatment of low blood cell
counts, or cytopenias, including anemia and thrombocytopenia, in
patients with myelodysplastic syndromes and in patients with
myelofibrosis. Keros’ lead small molecule product candidate,
KER-047, is being developed for the treatment of functional iron
deficiency. Keros’ third product candidate, KER-012, is being
developed for the treatment of pulmonary arterial hypertension and
for the treatment of cardiovascular disorders.
Investor Contact:Justin
Frantzjfrantz@kerostx.com 617-221-6042
Keros Therapeutics (NASDAQ:KROS)
Historical Stock Chart
From Apr 2024 to May 2024
Keros Therapeutics (NASDAQ:KROS)
Historical Stock Chart
From May 2023 to May 2024